with Xultophy® 100/3.6
For patients uncontrolled on liraglutide ≤1.8 mg + metformin ± pioglitazone ± SU
Significant A1C reduction vs liraglutide1
aEstimated treatment difference (95% CI): –0.95 [–1.15; –0.75]. P<0.0001, test for superiority evaluated at 5% level for significance.
- One of 291 patients (0.3%) treated with Xultophy® 100/3.6 reported severe hypoglycemia1,2,b
- 4.4 lb increase in the Xultophy® 100/3.6 arm and a 1.6 lb reduction in the liraglutide arm3
bSevere hypoglycemia: an event requiring assistance from another person to actively administer carbohydrate, glucagon, or other resuscitative actions.
Review all data from the DUAL™ III clinical trial vs liraglutide
Patients converted from liraglutide
DUAL™ III (Study A): A 26-week, randomized, parallel, open-label, treat-to-target trial in insulin-naïve adult patients with type 2 diabetes inadequately controlled (A1C 7%-9%) on up to 1.8 mg of liraglutide and metformin ± pioglitazone ± sulfonylurea, comparing the efficacy and safety of Xultophy® 100/3.6 (n=232) with unchanged liraglutide (n=116). All pretrial oral antidiabetic (OAD) therapies were continued throughout the trial. The primary endpoint was change in A1C after 26 weeks of treatment. Secondary endpoints included change in laboratory-measured FPG, dose, change in body weight, percent of patients achieving A1C <7%, and episodes of hypoglycemia.1,3
Patients could not increase their Xultophy® 100/3.6 dose by more than 4 units per week.